PharmaDax USA

PharmaDax USA is a specialty pharmaceutical company focused on the development and commercialization of high-quality generic drug products for the United States market. As a subsidiary of PharmaDax Inc., the company leverages its parent's expertise in complex formulation and drug delivery technologies to bring value-added generics to patients. Their commercial portfolio primarily consists of extended-release oral solid dosage forms targeting central nervous system (CNS) disorders such as epilepsy, Alzheimer's disease, and Parkinson's disease. PharmaDax USA manages the regulatory submission process, including Abbreviated New Drug Applications (ANDAs), and oversees the distribution of its products through strategic partnerships. The company is committed to improving healthcare accessibility by providing cost-effective alternatives to brand-name medications.